Novel tuberculosis vaccines are in varying stages of pre-clinical and clinical development. This study seeks to estimate the potential cost-effectiveness of a BCG booster vaccine, while accounting for costs of large-scale clinical trials, using the MVA85A vaccine as a case study for estimating potential costs. We conducted a decision analysis from the societal perspective, using a 10-year time frame and a 3% discount rate. We predicted active tuberculosis cases and tuberculosis-related costs for a hypothetical cohort of 960,763 South African newborns (total born in 2009). We compared neonatal vaccination with bacille Calmette-Guérin alone to vaccination with bacille Calmette-Guérin plus a booster vaccine at 4 months. We considered booster e...
Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protec...
BACKGROUND: Neonatal BCG vaccination is part of routine vaccination schedules in many developing cou...
The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the prevention of T...
Novel tuberculosis vaccines are in varying stages of pre-clinical and clinical development. This stu...
Abstract Background The development of a successful n...
Abstract Background Tuberculosis remains the leading ...
Includes bibliographical references.Tuberculosis (TB) remains a major public health concern. The BCG...
Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protec...
Introduction: Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for tuberculosis, but its ...
SummaryBackgroundNew tuberculosis (TB) vaccines are being developed to combat the global epidemic. A...
BACKGROUND: New tuberculosis (TB) vaccines are being developed to combat the global epidemic. A phas...
There is an urgent need to develop more effective tuberculosis vaccines as chemotherapy and Bacille ...
Background Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. S...
BACKGROUND: BCG vaccine has shown consistently high efficacy against childhood tuberculous meningiti...
To help reach the target of tuberculosis (TB) disease elimination by 2050, vaccine development needs...
Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protec...
BACKGROUND: Neonatal BCG vaccination is part of routine vaccination schedules in many developing cou...
The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the prevention of T...
Novel tuberculosis vaccines are in varying stages of pre-clinical and clinical development. This stu...
Abstract Background The development of a successful n...
Abstract Background Tuberculosis remains the leading ...
Includes bibliographical references.Tuberculosis (TB) remains a major public health concern. The BCG...
Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protec...
Introduction: Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for tuberculosis, but its ...
SummaryBackgroundNew tuberculosis (TB) vaccines are being developed to combat the global epidemic. A...
BACKGROUND: New tuberculosis (TB) vaccines are being developed to combat the global epidemic. A phas...
There is an urgent need to develop more effective tuberculosis vaccines as chemotherapy and Bacille ...
Background Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. S...
BACKGROUND: BCG vaccine has shown consistently high efficacy against childhood tuberculous meningiti...
To help reach the target of tuberculosis (TB) disease elimination by 2050, vaccine development needs...
Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protec...
BACKGROUND: Neonatal BCG vaccination is part of routine vaccination schedules in many developing cou...
The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the prevention of T...